Skip to Content
Merck
All Photos(1)

Key Documents

Y0000046

Estradiol valerate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

β-Estradiol 17-valerate, 1,3,5(10)-Estratriene-3,17β-diol 17-pentanote

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H32O3
CAS Number:
Molecular Weight:
356.50
Beilstein:
2480357
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

estradiol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C

InChI

1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3

InChI key

RSEPBGGWRJCQGY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Estradiol valerate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Health hazardEnvironment

Signal Word

Warning

Hazard Statements

Hazard Classifications

Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

C Egarter et al.
Acta obstetricia et gynecologica Scandinavica, 75(4), 386-393 (1996-04-01)
Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E2V/MPA) or conjugated estrogens plus medrogestone (CE/MED), were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis. In an open, multicenter study, 51 perimenopausal women
Sheridan M Hoy et al.
Drugs, 69(12), 1635-1646 (2009-08-15)
Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n = 1377), noncomparative, multicentre study in women aged
B von Schoultz
Climacteric : the journal of the International Menopause Society, 6 Suppl 2, 24-32 (2003-12-13)
A combination of 2 mg estradiol valerate with 2 mg dienogest (E2V/DNG) (Climodien, Schering AG, Berlin, Gemany) is the first continuous combined postmenopausal hormone replacement therapy (HRT) preparation to contain a progestogen with substantial antiandrogenic activity. A study of its
Franca Fruzzetti et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 28(5), 400-408 (2012-04-04)
Natural estrogens such as estradiol (E(2)) or its valerate ester (E(2)V) offer an alternative to ethinyl estradiol (EE). E(2)-containing combined oral contraceptives (COCs) have demonstrated sufficient ovulation inhibition and acceptable contraceptive efficacy. However, earlier formulations were generally associated with unacceptable
R M Machado-de-Sena et al.
Photodiagnosis and photodynamic therapy, 11(3), 275-282 (2014-05-06)
Vaginal candidiasis (VC) is a disease that affects thousands of women of childbearing age, mainly caused by Candida albicans fungus. Photodynamic therapy (PDT) uses photosensitizing substances that are nontoxic in the dark, but able to produce reactive oxygen species when

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service